Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Unlike some of its rivals, BioNTech and Pfizer have not promised to supply the vaccine on a not-for-profit basis....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Kulkarni said the sector would become more like “Apple v Samsung”, where biotechs competed on adding generation after generation of features....
...Peter Campbell in London 90....
...Since then competitors such as Pfizer, as well as Allergan and Shire have focused on securing promising research by acquiring other companies....
...Reporting by Sarah Gordon, Leo Lewis, Kana Inagaki, Peter Campbell, Guy Chazan, Stefan Wagstyl and David Bond...
...In US earnings, the newly divided Hewlett Packard Enterprise and HP Inc report, as do Analog Devices, Hormel Foods, Dollar Tree, Campbell Soup and Tiffany & Co....
...Alastair Campbell, analyst at Berenberg, said: “There’s no avoiding the fact that 2015 ended slowly and the outlook for 2016 is disappointing....
...Some analysts and investors are sceptical of his target — set during the successful battle to fend off a $100bn takeover by Pfizer last year — to increase revenues by three-quarters to $45bn by 2023....
...“We expect management will take every opportunity to invest in R&D over the next few years,” Mr Campbell said....
...Pfizer, which recently agreed a $160bn takeover of Botox maker Allergan has also seen its shares slide since announcing the deal, while investors punished Shire for its $32bn acquisition of Baxalta....
...The fund bought into a host of US stocks, including Pfizer, the pharmaceutical company, and General Electric, the multinational conglomerate....
...Campbell Soup shares dipped after the soup maker lowered its sales forecast for the current financial year to about 3 per cent from a previous forecast of between 4 and 5 per cent....
...(FT) Journalism v Silicon Valley The media has lost control of production and distribution to the opaque algorithms of Google and Facebook....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“Few investors were tempted to buy into equities” on Tuesday amid political and economic uncertainty, said Angus Campbell of Capital Spreads....
...Iran ready to cut Europe’s oil at once - Facebook to file IPO listing details next week - RBS Chairman Sir Philip Hampton turned down £1.4m bonus before Stephen Hester was awarded £1m - Pfizer...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...“The first mover has a huge commercial advantage,” said Douglas Campbell, a barrister at Three New Square, which specialises in intellectual property cases....
...In December, Jeff Kindler, chief executive of Pfizer, abruptly resigned....
...Some pharmaceutical stocks fell, with Eli Lilly declining 0.8 per cent to $34.99 and Pfizer dropping by 1 per cent to $16.83....
...In drugmakers, Pfizer rose 1.1 per cent to $16.10 after a study said patients should stick with Pfizer’s cholesterol-lowering drug Lipitor rather than switching to a generic alternative....
International Edition